Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of Rochester 910 Genesee St STE200 Rochester, NY 14611-3847
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTOur goal was to develop and characterize a mouse model for the disease lymphangioleiomyomatosis (LAM). This disease is found almost exclusively in women and is due to a mutation in one of the two TSC suppressor genes. Women with LAM develop smooth muscle-like tumors in the lungs that grow progressively, often leading to lung failure. Evidence suggested that these tumors do not originate in the lungs but instead are metastatic from another location in the body. Our hypothesis was that lung LAM tumors were actually metastatic from smooth muscle myometrial cells in the uterus, thus explaining both the appearance of the LAM cells as well as the overwhelming female prevalence. Thus, we created a uterine-specific TSC-2 knockout mouse. These mice developed uterine tumors that were completely dependent on estrogen for growth. Importantly, as mice aged above 30 weeks, 75% of them developed myometrial lung tumors that shared many features consistent with LAM. These data were just published in and featured on the cover of the September, 2013 issue of "Molecular Endocrinology." This is an exciting new model, and we hope to use it to both better understand LAM and to help test novel treatment options for LAM. References……………………………………………………………………………. 5
SUBJECT TERMS
Appendices…………………………………………………………………………… 64 Uterine-specific knockout of Tsc-2: a mouse model for lymphangioleiomyomatosisStephen R Hammes, MD, PhD, University of Rochester Rochester, NY
Introduction:Lymphangioleiomyomatosis (LAM) is a rare disease that consists of smooth muscle cell tumors within the lungs that progressively grow, often leading to pulmonary failure and sometimes even lung transplantation. Interestingly, even after transplantation, LAM tumors often return to the lungs, suggesting that LAM cells do not originate in the lung. Two other unusual features of LAM are: 1) LAM is found almost exclusively in women; and 2) LAM cells contain mutations in one of the two TSC genes. To explain all of these observations, we proposed that LAM cells might metastasize from smoot...